36results about How to "Reduce collagen content" patented technology

A Chinese medicine for treating the slow-transmission constipation is prepared from 13 Chinese-medicinal materials including tangerine peel, astragalus root, Chinese angelica root, rehmannia root, etc through proportional mixing, distilling, extracting, concentrating, drying and loading in capsules.

The invention pertains to the field of traditional Chinese medicines and relates to a medicine for treating chronic liver diseases. The invention adopts the active ingredients or components in cordyceps polysaccharide, amygdalin and gypenosides with a specific mixture ratio to compose a drug composite with ideal therapeutic effects of resisting hepatic fibrosis and liver injury. By the model tests of classic animals and verification, results confirm that the medicine can remarkably reduce the collagen concentration of the liver tissues of rat models, lighten the degrees of hepatic fibrosis and liver injury and improve the effects of resisting hepatic fibrosis, effectively prevent the development of hepatic fibrosis and promote the reversion of hepatic fibrosis. The effects are better than that of individually using each ingredient; the medicine can be used for treating and preventing various diseases, such as chronic hepatitis, hepatic fibrosis, hepatocirrhosis and the like. The medicine can be prepared into oral solid preparations, such as granules, tablets, capsules and the like.

Aspects of the invention provide methods for treatment of nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate compound for the treatment of nonalcoholic steatohepatitis and associated liver fibrosis.

The invention discloses a traditional Chinese medicine composition used for treating chronic liver diseases. The composition is composed of the raw medicine materials of, by weight, 6-18 parts of common burreed tuber, 6-18 parts of blue turmeric rhizome, and 9-30 parts of turtle shell. According to the invention, blood-circulation-activating, stasis-removing, hard-mass-softening, and stagnation-eliminating traditional Chinese medicines are used for producing the medicine composition with functions of hepatic fibrosis inhibiting and hepatic damage inhibiting. Classic animal model experiments and validation are carried out. As a result, the traditional Chinese medicine composition provided by the invention assists in substantially reducing model rat liver tissue collagen content, reducing hepatic fibrosis degree and hepatic damage degree, effectively inhibiting hepatic fibrosis development, and promoting hepatic fibrosis reversing. The composition provided by the invention can be used for treating and preventing various diseases such as chronic hepatitis, liver fibrosis, cirrhosis, liver tumor, and the like. The medicine can be prepared into oral solid preparations such as tablets, granules, capsules, and the like.

Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and / or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and / or increased myofibroblast content in tissue.

The invention discloses a traditional Chinese medicinal composition for treating the chronic hepatopathy. The composition is prepared through mainly using the following raw medicines, by weight, 9-30 parts of Rhizoma Sparganii, 9-30 parts of Rhizoma Curcumae, 6-30 parts of cortex magnoliae officinalis, 6-30 parts of Cornus officinalis, 1.5-15 parts of Rhizoma Coptidis, 3-30 parts of Radix Aucklandiae, 3-30 parts of dry ginger, 3-15 parts of processed Pinellia Tuber, and 6-30 parts of turtle shell. The medicinal composition having effective hepatic fibrosis and hepatic injury resistances is obtained through adopting traditional Chinese medicines having blood circulation invigorating, blood stasis dispersing, phlegm reducing, hardness softening and bind dissipating effects. Results of classic animal model experiments and verifications prove that the traditional Chinese medicinal composition can substantially reduce the content of collagens in the hepatic tissues of model rats, mitigates the hepatic fibrosis and hepatic injury degrees, and effectively prevents the development of the hepatic fibrosis and promotes the reversion of the hepatic fibrosis. The traditional Chinese medicinal composition can be used for treating and preventing all kinds of chronic hepatitis, hepatic fibrosis, hepatic cirrhosis, hepatic tumors and the like. The traditional Chinese medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.

The invention discloses a human adipose-derived stem cell secreted polypeptide ADSCP2 and an application thereof. The human adipose-derived stem cell secreted polypeptide ADSCP2 has an amino acid sequence as shown in SEQ ID NO. 1. The polypeptide ADSCP2 can inhibit the mRNA expression quantity of collagen genes COL1A1, COL1A2 and COL3A1 in human scar dermal fibroblasts, and the mRNA expression quantity of a main marker ACTA2 of myofibroblasts in the human scar dermal fibroblasts is remarkably reduced. The human adipose-derived stem cell secreted polypeptide ADSCP2 can be used for preparing drugs or reagents for reducing the content of scar dermal fibroblast collagen and reducing the amount of myofibroblasts, and a new target is provided for inhibiting scar hyperplasia.

The invention discloses application of a substance for inhibiting phosphorylation of a 357 tyrosine residue of a YAP protein to prevention of atherosclerosis. The substance for inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein is an Src / c-Abl tyrosine kinase double inhibitor or a c-Abl inhibitor or an Src inhibitor; bosutinib is adopted as the Src / c-Abl tyrosine kinase double inhibitor; and experiments prove that the bosutinib prevents atherosclerosis, treats atherosclerosis, decreases the area of plaques of atherosclerosis, reduces lipid deposition, decreases the collagen content, inhibits forming of the plaques of atherosclerosis, inhibits activation of vascular endothelial cells and inhibits the expression level of adherence factors by inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein. The substance has significant application value.

The invention discloses a pharmaceutical composition for preventing, treating and improving metabolic diseases, fibrosis diseases and liver diseases. The composition at least comprises the following two active ingredients: (I) one or more of coleus forskohlii extract, forskolin and isoforskolin; and (II) one or more of a pentacyclic triterpenoid compound and a plant extract containing the pentacyclic triterpenoid compound. Compared with independent use of two components, the pharmaceutical composition disclosed by the invention can achieve a remarkable synergistic effect on prevention and treatment of the metabolic diseases, fibrosis diseases and liver diseases.

An application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.

The invention discloses a traditional Chinese medicinal composition for treating the chronic hepatopathy. The composition is prepared through mainly using the following raw medicines, by weight, 9-30 parts of Rhizoma Sparganii, 9-30 parts of Rhizoma Curcumae, 6-30 parts of cortex magnoliae officinalis, 6-30 parts of Cornus officinalis, 1.5-15 parts of Rhizoma Coptidis, 3-30 parts of Radix Aucklandiae, 3-30 parts of dry ginger, 3-15 parts of processed Pinellia Tuber, and 6-30 parts of turtle shell. The medicinal composition having effective hepatic fibrosis and hepatic injury resistances is obtained through adopting traditional Chinese medicines having blood circulation invigorating, blood stasis dispersing, phlegm reducing, hardness softening and bind dissipating effects. Results of classic animal model experiments and verifications prove that the traditional Chinese medicinal composition can substantially reduce the content of collagens in the hepatic tissues of model rats, mitigates the hepatic fibrosis and hepatic injury degrees, and effectively prevents the development of the hepatic fibrosis and promotes the reversion of the hepatic fibrosis. The traditional Chinese medicinal composition can be used for treating and preventing all kinds of chronic hepatitis, hepatic fibrosis, hepatic cirrhosis, hepatic tumors and the like. The traditional Chinese medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.

The invention discloses a human skin tissue endogenous polypeptide PDHPS1 and an application thereof. The amino acid sequence of the human skin tissue endogenous polypeptide PDHPS1 is shown in SEQ IDNO.1. The polypeptide PDHPS1 inhibits the propagation of a scar dermal fibroblast, inhibits the expression of mRNA of collagen genes COL1A1 and COL1A2 in the scar dermal fibroblast, and obviously reduces the protein expression of a main marker alpha-SMA of a myofibroblast in the scar dermal fibroblast. The human skin tissue endogenous polypeptide PDHPS1 can be used to prepare a drug or agent whichcan inhibit the propagation of the scar dermal fibroblast, reduce the collagen content and reduce the amount of the myofibroblast, and provides a new target spot for inhibiting the scar hypertrophy.

A Chinese medicine for treating the slow-transmission constipation is prepared from 13 Chinese-medicinal materials including tangerine peel, astragalus root, Chinese angelica root, rehmannia root, etc through proportional mixing, distilling, extracting, concentrating, drying and loading in capsules.

The invention discloses application of neryl acetate in preparing a hypertensive myocardial fibrosis resisting medicine. The invention discloses application of ester matter in preparing a hypertensionand / or heart disease resisting medicine and / or health products. A structural formula of the ester matter is shown in description, wherein the R1 is C1 to C3 alkyl, and the R2 and the R3 are hydrogenor C1 to C3 alkyl. The ester matter can reduce body systolic pressure and diastolic pressure to increase cardiac ejection fraction and shortening fraction, reduce a myocardium collagen content and enhance body heart functions, so that a novel selection direction is provided for treating hypertension, heart diseases and hypertensive myocardial fibrosis.

Aspects of the invention provide methods for treating nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of therapeutic formulations comprising galactose-rhamnogalacturonates for the treatment of non-alcoholic steatohepatitis and associated liver fibrosis.

The invention discloses a traditional Chinese medicine composition used for treating chronic liver diseases. The composition is composed of the raw medicine materials of, by weight, 6-18 parts of common burreed tuber, 6-18 parts of blue turmeric rhizome, and 9-30 parts of turtle shell. According to the invention, blood-circulation-activating, stasis-removing, hard-mass-softening, and stagnation-eliminating traditional Chinese medicines are used for producing the medicine composition with functions of hepatic fibrosis inhibiting and hepatic damage inhibiting. Classic animal model experiments and validation are carried out. As a result, the traditional Chinese medicine composition provided by the invention assists in substantially reducing model rat liver tissue collagen content, reducing hepatic fibrosis degree and hepatic damage degree, effectively inhibiting hepatic fibrosis development, and promoting hepatic fibrosis reversing. The composition provided by the invention can be used for treating and preventing various diseases such as chronic hepatitis, liver fibrosis, cirrhosis, liver tumor, and the like. The medicine can be prepared into oral solid preparations such as tablets, granules, capsules, and the like.

The invention discloses a human adipose stem cell secreted polypeptide ADSCP2 and its application. A human adipose stem cell secreted polypeptide ADSCP2, the amino acid sequence of which is shown in SEQ ID NO.1. The polypeptide ADSCP2 can inhibit the mRNA expression of collagen genes COL1A1, COL1A2, and COL3A1 in human scar dermal fibroblasts, and significantly reduce the mRNA expression of the main myofibroblast marker ACTA2 in human scar dermal fibroblasts. The human adipose stem cell secreted polypeptide ADSCP2 can be used to prepare drugs or reagents for reducing the collagen content of fibroblasts in scar dermis and the amount of myofibroblasts, providing a new target for inhibiting scar hyperplasia.

A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.